Thomson finalizes Solucient purchase

Share this article:
Thomson is buying the balance of Solucient from media giant VNU, private equity firm Veronis Suhler Stevenson and healthcare provider alliance VHA.

Thomson snapped up part of the informatics business—that focused on provision of services to payors—last February.

Now the Stamford-based firm has completed its acquisition of Solucient by picking up its analytics business directed at providers. Those businesses will be folded into Thomson's Medstat informatics unit.

Headquartered in Evanston, IL, Solucient boasts a staff of 500 and a secondary office in Ann Arbor, MI, where Medstat is based. Carol Diephuis, EVP at Thomson Medstat, said the firm might consider consolidating offices in the future, but for now, the companies are highly complementary.

“When you think about the combination of expertise and the massive market need in this space, there's growth opportunities for employees of both organizations,” she said. “Solucient helps round out our offering with a lot of information services for hospital managers as well as pharmaceutical companies.”

Before the acquisition, Thomson Health & Scientific employed 4,700. The firm has been moving away from medical publishing and more heavily into healthcare informatics since its divestiture of its Medical Economics business to Advanstar in October 2003.

Thomson continues to publish PDR. Other Thomson assets include its MercuryMD and Micromedix informatics businesses, aimed at healthcare providers, the CenterWatch suite of products and PDA program Clinical Xpert.

Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.